<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972566</url>
  </required_header>
  <id_info>
    <org_study_id>NO-5420</org_study_id>
    <nct_id>NCT03972566</nct_id>
  </id_info>
  <brief_title>Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis &amp; Raynaud Phenomenon</brief_title>
  <official_title>Localized Effects of Photobiomodulation and Exogenous Nitric Oxide on CREST Patients Calcinosis Cutis &amp; Raynaud Phenomenon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RoseLab Skin Optics Laboratory</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RoseLab Skin Optics Laboratory</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background CREST is an acronym for the cardinal clinical features of the syndrome&#xD;
      (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia)&#xD;
      and part of the heterogeneous group of sclerodermas.&#xD;
&#xD;
      Calcinosis is the pathologic calcification of soft tissues. When symptomatic, they can be&#xD;
      tender and painful, ulcerate, and drain a white chalky substance. With time, heterotopic bone&#xD;
      formation may occur. Inflammatory reactions also intermittently occur at the site of&#xD;
      calcinosis. It has been suggested that TGF-beta3 plays a major role in the pathogenesis of&#xD;
      calcinosis.&#xD;
&#xD;
      A variety of medical therapies have been used to try to alleviate patient symptoms. These&#xD;
      include pharmacological approaches (e..g., warfarin), surgical curettage or excision, as well&#xD;
      as carbon dioxide laser treatments. No consistently reliable pharmacological treatment seems&#xD;
      to be available to prevent or eliminate calcinosis. Curettage and excision and carbon dioxide&#xD;
      laser of localized painful large deposits can relieve symptoms but recurrence is common. In&#xD;
      addition, aggressive curettage or excision can damage deeper neurovascular structures. While&#xD;
      calcinosis is associated with significant morbidity its treatment remains a challenge.&#xD;
&#xD;
      Photobiomodulation (PBM) has been shown to promote wound healing, suppress inflammatory&#xD;
      reactions and regulate collagen synthesis in a number of in vitro and in vivo studies.&#xD;
&#xD;
      Human skin contains photolabile nitric oxide (NO) derivatives which decompose after UVA&#xD;
      irradiation and release vasoactive NO. However, aside from blue light, barely nothing has&#xD;
      been reported about the effects of red and NIR wavelengths.&#xD;
&#xD;
      Method A custom-built air tight sleeve which envelopes the forearm of a subject will be used&#xD;
      to measure the NO emanating from the skin under photobiomodulation conditions (red &amp; NIR) and&#xD;
      quantified by chemiluminescence detection.&#xD;
&#xD;
      Simultaneously, CREST patient's hands exhibiting calcinosis and/or Raynaud phenomenon will be&#xD;
      exposed to exogenous gaseous nitric oxide (INOMAX) to determine the vascular impact of this&#xD;
      approach.&#xD;
&#xD;
      This case series will assess Light Emitting Diode (LED) based PBM therapy as a treatment&#xD;
      alternative for cutaneous calcinosis and the effects of gaseous NO on calcinosis and/or&#xD;
      Raynaud phenomenon in CREST patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 20, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chemiluminescence detection</measure>
    <time_frame>15 minutes</time_frame>
    <description>Sievers Nitric Oxide Analyzer NOA 280i detects [NO] in Ambient Air or Solution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Measurement</measure>
    <time_frame>5 minutes</time_frame>
    <description>VENDYS II</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5</enrollment>
  <condition>CREST Syndrome</condition>
  <condition>Calcinosis Cutis</condition>
  <condition>Raynaud Phenomenon</condition>
  <arm_group>
    <arm_group_label>CREST with Calcinosis cutis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CREST without Calcinosis cutis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INOMAX</intervention_name>
    <description>INOMAX + PBM</description>
    <arm_group_label>CREST with Calcinosis cutis</arm_group_label>
    <arm_group_label>CREST without Calcinosis cutis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gaseous NO emanating from subject's arms, Digital Thermal Monitoring (DTM) to measure&#xD;
      vascular reactivity&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from CREST that have consulted in Dr. Barolet's Clinic of Dermatology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  18-60 years of age&#xD;
&#xD;
          -  CREST syndrome with calcinosis cutis.&#xD;
&#xD;
          -  CREST syndrome without calcinosis cutis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Acute inflammation&#xD;
&#xD;
          -  Arrhythmia&#xD;
&#xD;
          -  Acute malignancy&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Active CVD&#xD;
&#xD;
          -  Photodermatosis and/or photosensitivity including skin cancer-prone disease/syndrome&#xD;
             (XP and Bloom Syndrome)&#xD;
&#xD;
          -  Porphyria and/or hypersensitivity to porphyrins&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Barolet, MD</last_name>
    <phone>450-686-4744</phone>
    <email>daniel.barolet@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Augustin Barolet, B.Eng</last_name>
    <phone>450-686-4744</phone>
    <email>augustin.barolet@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Dr Daniel Barolet</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T0G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Barolet, MD</last_name>
      <phone>450-686-4744</phone>
      <email>daniel.barolet@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Augustin Barolet, B.Eng</last_name>
      <phone>450-686-4744</phone>
      <email>augustin.barolet@mail.mcgill.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RoseLab Skin Optics Laboratory</investigator_affiliation>
    <investigator_full_name>Dr Daniel Barolet</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Nitric Oxide</keyword>
  <keyword>Photobiomodulation</keyword>
  <keyword>LLLT</keyword>
  <keyword>Photomedicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CREST Syndrome</mesh_term>
    <mesh_term>Raynaud Disease</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

